Analysts’ Ideas of the Week
Top Picks Snapshot: Tech & Mining Movers
Published: Jul 21, 2025
Author: FRC Analysts
*Articles and research coverage are paid for and commissioned by issuers. See the bottom and below for other important disclosures, rating, and risk definitions, and specific information.
*Disseminated on behalf of North Peak Resources, Giga Metals Corp., Cupani Metals Corp., NurExone Biologic Inc., Zepp Health Corporation, Kidoz Inc., South Star Battery Metals, Lake Resources, Panoro Minerals, and Atrium Mortgage Investment Corporation. See the bottom of this report for other important disclosures.
We review the performance of our Top Picks, including a leading smartwatch maker whose shares rose 36% last week, and 431% in the past month. We also provide material updates on other companies under coverage, including a biotech, and juniors targeting gold, copper, and nickel.
Updates on Resource Companies Under Coverage
North Peak Resources Ltd. (BTLLF, NPR.V)
PR Title: Fully acquires the Prospect Mountain Mine Complex (MMC) in Nevada
Analyst Opinion: Positive – Following its acquisition of an 80% interest in the Prospect Mountain project in 2023, NPR has now exercised its right to acquire the remaining 20% interest. MMC is a past-producing gold-silver-lead project in Nevada’s Eureka district, adjacent to i-80 Gold’s Ruby Hill (TSX: IAU; MCAP: $673M), and just north of McEwen Mining’s Eureka Property (NYSE: MUX; MCAP: $809M). This acquisition reflects management’s strong conviction in the project’s potential, particularly in light of a promising 2024 drill program. NPR plans to continue drilling aggressively, test all key targets, and work toward outlining a maiden resource that could attract strategic interest. The company is well-capitalized following a recent $5.40M equity raise. We will publish a detailed update report shortly.
Giga Metals Corporation (GIGA.V, HNCKF)
PR Title: Announces a $0.85M private placement (QP: Lyle Trytten, P.Eng., Manager of Development, GIGA)
Analyst Opinion: Positive – Proceeds will fund exploration at the company’s Turnagain project in northern B.C., which hosts one of the largest undeveloped nickel-cobalt deposits in the world. A 2023 Preliminary Economic Assessment (PEA) returned an after-tax NPV7% of US$574M, and an IRR of 11%, based on US$9.80/lb nickel vs the current spot price of US$7.02/lb. The project’s break-even nickel price is US$8.20/lb. Giga has identified several promising high-grade targets; if incorporated into the resource, they could significantly improve the project’s NPV and IRR. We note that most large undeveloped nickel projects are not economically viable if nickel prices remain below US$8.00/lb.
Cupani Metals Corp. (CUPA.CN)
PR Title: Expands Blue Lake land package through acquisition of Nemo project claims
Analyst Opinion: Positive – The Nemo Property is contiguous with Cupani’s Blue Lake copper-nickel-platinum-palladium project in Quebec. Although Nemo remains untested and has never been drilled, it adds strategic value to the Blue Lake land package. Blue Lake hosts massive sulfide mineralization across five major zones, covering over 500 km². While still in the early stages of exploration, we see discovery potential. Based on our review of available data and speculative assumptions, we estimate the project could host over 3 billion pounds (Blbs) of copper equivalent (CuEq). The company is well-capitalized, supported by a recent $3.80M equity financing.
Updates on Financials, Technology, Energy, and Special Situations Companies Under Coverage
NurExone Biologic Inc./TSXV: NRX
PR Title: Preclinical study indicates significant improvement in walking quality in spinal cord injury model
Analyst Opinion: Positive – NRX announced that animals treated with a higher dose of ExoPTEN showed significant recovery of motor function following spinal cord injury. Results demonstrated a clear dose-dependent improvement in mobility, and walking parameters, with no side effects observed at the higher dose. These promising preclinical findings support ExoPTEN’s potential as a treatment for acute spinal cord injury.
NRX will continue optimizing dosing regimen, and manufacturing processes, while preparing for further studies, and regulatory engagement, with the goal of initiating first-in-human clinical trials.
FRC Top Picks
The following table shows last week’s top five performers among our Top Picks. Leading the pack for the third consecutive week was Zepp Health Corporation (NYSE: ZEPP), which surged 36% WoW, and 431% MoM. Zepp is the seventh-largest smartwatch maker globally by unit sales. Despite no recent press releases, ZEPP’s surge was not unexpected given its MCAP was well below liquid asset value. Although global smartwatch shipments remained relatively flat YoY in Q1-2025, Zepp reported 25% growth in its self-branded products.
A broader positive backdrop for Chinese tech stocks may also be contributing to ZEPP’s rally. The S&P China Select ADR Index is up 8% MoM, and 26% YoY, significantly outperforming the S&P 500’s respective gains of 5% and 18% over the same periods. Another potential catalyst was the strong move in Viomi Technology (NASDAQ: VIOT), which announced a special dividend. Viomi’s shares are up 153% in the past month. While Viomi operates in the smart home appliance space and Zepp focuses on wearables, both companies are categorized as Chinese tech stocks, and have strategic partnerships with Xiaomi (SEHK: 1810), one of China’s leading technology conglomerates. We believe Viomi’s surge may have prompted renewed investor attention toward other overlooked Xiaomi-affiliated tech stocks, including Zepp.
Disclaimer
The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any “forward looking statements” are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. The companies listed above are covered by FRC under an issuer-paid model, where fees have been paid to FRC to commission this report and research coverage. This creates a potential conflict of interest which readers should consider. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. To subscribe for real-time access to research, visit https://www.researchfrc.com/plans for subscription options. This report contains “forward looking” statements. Forward-looking statements regarding the Company, industry, and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products/services in the marketplace; acceptance in the marketplace of the Company’s new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company’s periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE’S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
